{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:46:20Z","timestamp":1791773180919,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejim.2026.107030","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:23:02Z","timestamp":1782588182000},"page":"107030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetic robustness of direct oral anticoagulants vs. phenprocoumon in the emergency setting: impact of renal and hepatic impairment"],"prefix":"10.1016","author":[{"given":"Fatma","family":"Merzou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2929-0763","authenticated-orcid":false,"given":"Luca","family":"Tarantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9629-2663","authenticated-orcid":false,"given":"Benjamin","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5228-6483","authenticated-orcid":false,"given":"Martin","family":"Lesmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrey","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiu","family":"Groppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9854-4038","authenticated-orcid":false,"given":"Yaroslav","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Fassbender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2101-6066","authenticated-orcid":false,"given":"Piergiorgio","family":"Lochner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2026.107030_bib0001","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/imj.70103","article-title":"2025 Guidelines for direct oral anticoagulants: a practical guidance on the prescription, laboratory testing, peri-operative and bleeding management","volume":"55","author":"Tran","year":"2025","journal-title":"Intern Med J."},{"key":"10.1016\/j.ejim.2026.107030_bib0002","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1055\/s-0029-1240018","article-title":"New anticoagulants in atrial fibrillation","volume":"35","author":"Harenberg","year":"2009","journal-title":"Semin Thromb Hemost."},{"key":"10.1016\/j.ejim.2026.107030_bib0003","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet."},{"key":"10.1016\/j.ejim.2026.107030_bib0004","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.3390\/ijms22168531","article-title":"The Clinical Significance of Drug-Food Interactions of Direct Oral Anticoagulants","volume":"22","author":"Grze\u015bk","year":"2021","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.ejim.2026.107030_bib0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/rth2.12159","article-title":"The effect of stopping phenprocoumon 5 days preoperatively: A retrospective study","volume":"3","author":"Knol","year":"2019","journal-title":"Res Pract Thromb Haemost."},{"key":"10.1016\/j.ejim.2026.107030_bib0006","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.3390\/ph15111437","article-title":"Pharmacokinetics of Phenprocoumon in Emergency Situations-Results of the Prospective Observational RADOA-Registry (Reversal Agent Use in Patients Treated with Direct Oral Anticoagulants or Vitamin K Antagonists Registry)","volume":"15","author":"Lindhoff-Last","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ejim.2026.107030_bib0007","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/joim.20067","article-title":"Excess risk of bleeding in patients with venous thromboembolism on direct oral anticoagulants during initial and extended treatment versus population controls","volume":"297","author":"Glise Sandblad","year":"2025","journal-title":"J Intern Med."},{"key":"10.1016\/j.ejim.2026.107030_bib0008","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/bcp.14450","article-title":"Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation","volume":"87","author":"Souverein","year":"2021","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.ejim.2026.107030_bib0009","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJMoa2510703","article-title":"Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism","volume":"394","author":"Castellucci","year":"2026","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ejim.2026.107030_bib0010","doi-asserted-by":"crossref","first-page":"20","DOI":"10.7326\/M21-0717","article-title":"Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data","volume":"175","author":"Dawwas","year":"2022","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.ejim.2026.107030_bib0011","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.hrthm.2024.08.033","article-title":"Apixaban vs rivaroxaban in patients with atrial fibrillation at high or low bleeding risk: A population-based cohort study","volume":"22","author":"Shurrab","year":"2025","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.ejim.2026.107030_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003343","article-title":"Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study","volume":"3","author":"Maccallum","year":"2013","journal-title":"BMJ Open."},{"key":"10.1016\/j.ejim.2026.107030_bib0013","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40119-013-0019-y","article-title":"Anticoagulation in Patients Aged \u226575 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants","volume":"2","author":"Ng","year":"2013","journal-title":"Cardiol Ther."},{"key":"10.1016\/j.ejim.2026.107030_bib0014","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3390\/ijerph19031436","article-title":"Safety and Efficacy of DOACs in Patients with Advanced and End-Stage Renal Disease","volume":"19","author":"Rogula","year":"2022","journal-title":"Int J Environ Res Public Health."},{"key":"10.1016\/j.ejim.2026.107030_bib0015","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1007\/s12325-023-02544-8","article-title":"Prescription of DOACs in Patients with Atrial Fibrillation at Different Stages of Renal Insufficiency","volume":"40","author":"Hahn","year":"2023","journal-title":"Adv Ther."},{"key":"10.1016\/j.ejim.2026.107030_bib0016","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/FTD.0000000000000247","article-title":"Laboratory Monitoring: A Turning Point in the Use of New Oral Anticoagulants","volume":"38","author":"Scridon","year":"2016","journal-title":"Ther Drug Monit."},{"key":"10.1016\/j.ejim.2026.107030_bib0017","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1177\/1060028016632785","article-title":"Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy","volume":"50","author":"Finks","year":"2016","journal-title":"Ann Pharmacother."},{"key":"10.1016\/j.ejim.2026.107030_bib0018","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/00185787251372413","article-title":"A Single Health System Retrospective Qualitative Analysis of Inpatient Apixaban and Rivaroxaban Calibrated Anti-Xa Level Monitoring and Clinical Implications","volume":"61","author":"McCarville","year":"2026","journal-title":"Hosp Pharm."},{"key":"10.1016\/j.ejim.2026.107030_bib0019","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J."},{"key":"10.1016\/j.ejim.2026.107030_bib0020","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.chest.2016.08.1462","article-title":"Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review","volume":"151","author":"Samuelson","year":"2017","journal-title":"Chest."},{"key":"10.1016\/j.ejim.2026.107030_bib0021","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J."},{"key":"10.1016\/j.ejim.2026.107030_bib0022","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest."},{"key":"10.1016\/j.ejim.2026.107030_bib0023","series-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"key":"10.1016\/j.ejim.2026.107030_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144856","article-title":"Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis","volume":"10","author":"Cohen","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.ejim.2026.107030_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13318-018-0501-y","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Patients with Renal Failure","volume":"44","author":"Padrini","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet."},{"key":"10.1016\/j.ejim.2026.107030_bib0026","doi-asserted-by":"crossref","first-page":"55","DOI":"10.15420\/aer.2017.50.1","article-title":"The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation","volume":"7","author":"Vranckx","year":"2018","journal-title":"Arrhythm Electrophysiol Rev."},{"key":"10.1016\/j.ejim.2026.107030_bib0027","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/14779072.2023.2270909","article-title":"The impact of anticoagulation therapy on kidney function in patients with atrial fibrillation and chronic kidney disease","volume":"21","author":"Simic","year":"2023","journal-title":"Expert Rev Cardiovasc Ther."},{"key":"10.1016\/j.ejim.2026.107030_bib0028","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009263","article-title":"Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: A Retrospective Cohort Study","volume":"7","author":"Wang","year":"2018","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.ejim.2026.107030_bib0029","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.1093\/eurheartj\/sui031","article-title":"Reviewing the reality: why we need to change","volume":"7","author":"Lin","year":"2005","journal-title":"Eur Heart J Suppl."}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526003353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526003353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:23:07Z","timestamp":1782588187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620526003353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":29,"alternative-id":["S0953620526003353"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107030","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic robustness of direct oral anticoagulants vs. phenprocoumon in the emergency setting: impact of renal and hepatic impairment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}],"article-number":"107030"}}